Crossmark

Can a decision support system accelerate rare disease diagnosis? Evaluating the potential impact of Ada DX in a retrospective study

Crossref DOI link: https://doi.org/10.1186/s13023-019-1040-6

Published Online: 2019-03-21

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ronicke, Simon http://orcid.org/0000-0001-8822-4268
Hirsch, Martin C.

Türk, Ewelina

Larionov, Katharina

Tientcheu, Daphne

Wagner, Annette D.
License Information

Text and Data Mining valid from 2019-03-21
More Information

Article History

Received: 13 November 2018

Accepted: 28 February 2019

First Online: 21 March 2019

Ethics approval and consent to participate

: Ethical approval was obtained from the ethics committee at the Hannover Medical School, Hannover, Germany. Written consent was obtained from all selected patients. Name of the ethics committee that approved the study: “Ethikkommission der Medizinischen Hochschule Hannover”, Hannover, Germany. Number of the approved votum of the Ethics Committee: 3673-2017.

: Not applicable.

: SR, ET receive salary from Ada Health GmbH. MCH is holding shares in Ada Health GmbH. KL, DT, ADW declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.